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T
his review covers the epidemiology,
pathophysiology, clinical presenta-
tion, and diagnosis of cardiac auto-
nomic neuropathy (CAN) in diabetes and
discussescurrentevidenceonapproaches
to prevention and treatment of CAN.
CASE PRESENTATION— A 26-
year-old woman with “brittle” type 1 dia-
betes and severe CAN experienced
sudden cardiac death. She had a 16-year
history of poor diabetes control present-
ing with wide blood glucose ﬂuctuations,
recurrent episodes of severe hypoglyce-
mia, and hypoglycemia unawareness.
Overtimeshedevelopedpersistentortho-
static hypotension with daily falls in sys-
tolic blood pressure ranging from 30–60
mmHg. These episodes had signiﬁcant
impactonherdailyactivitiesandrequired
intermittent therapy with the -1 agonist
midodrine. Other complications in-
cluded severe gastroparesis, refractory di-
arrhea, and painful diabetic peripheral
neuropathy. Her last clinical examination
revealed resting tachycardia with a ﬁxed
rateof115bpm,supinebloodpressureof
110/78 mmHg, which dropped to 70/48
mmHg while standing, symmetrical ab-
sent pinprick and temperature discrimi-
nation in stocking distribution, and left
Charcot joint. Her last pertinent labora-
tory ﬁndings were A1C 8.7%, creatinine
1.9 mg/dl, microalbumin/creatinine 496
mg/g, and hemoglobin 10.8 g/dl.
CAN represents a signiﬁcant cause of
morbidity and mortality in diabetic pa-
tients and is associated with a high risk of
cardiac arrhythmias and sudden death,
possibly related to silent myocardial isch-
emia. Therefore, it has important clinical
and prognostic relevance. Recent reports
of major clinical trials undermine estab-
lished thinking concerning glycemic con-
trolandcardiacrisk.Thus,areviewofthis
topic is both timely and important for
physicians to better understand how to
assess the complexity of conditions
present in patients with diabetes in order
to establish safe treatment targets.
EPIDEMIOLOGY— Diabetes af-
fects more than 23 million people in the
U.S. (www.diabetes.org) and an esti-
mated 250 million worldwide (www.
who.int/diabetes). Diabetic neuropathies,
including CAN, are a common chronic
complicationoftype1andtype2diabetes
and confer high morbidity and mortality
to diabetic patients. The reported preva-
lence of CAN varies greatly depending
on the criteria used to identify CAN and
the population studied. CAN prevalence
rangesfromaslowas2.5%oftheprimary
preventioncohortintheDiabetesControl
and Complications Trial (DCCT) (1) to as
high as 90% of patients with long-stand-
ing type 1 diabetes who were potential
candidates for a pancreas transplantation
(2). In a large cohort of patients with type
1 and type 2 diabetes, Ziegler et al. (3),
using predeﬁned heart rate variability
(HRV) tests and spectral analysis of the
R-R intervals, found that 25.3% of pa-
tients with type 1 diabetes and 34.3%
of patients with type 2 diabetes had ab-
normal ﬁndings. Age, sex, and other
risk factors may also inﬂuence CAN
development.
PATHOGENESIS— In diabetes,
CAN is ultimately the result of complex
interactions among degree of glycemic
control, disease duration, age-related
neuronal attrition, and systolic and dia-
stolic blood pressure (4,5). Hyperglyce-
mia plays the key role in the activation of
various biochemical pathways related to
the metabolic and/or redox state of the
cell, which, in concert with impaired
nerve perfusion, contribute to the devel-
opment and progression of diabetic neu-
ropathies. Experimental data implicate a
number of pathogenic pathways that may
impact autonomic neuronal function in
diabetes including: formation of ad-
vanced glycation end products, increased
oxidative/nitrosativestresswithincreased
free radical production, activation of the
polyolandproteinkinaseCpathways,ac-
tivation of polyADP ribosylation, and ac-
tivation of genes involved in neuronal
damage (6–8). A detailed review of these
mechanisms and their complex interac-
tionshasbeencoveredbroadly(6–8)and
is beyond the scope of this article.
CAN AND CARDIAC
DYSFUNCTION— Autonomic in-
nervation is the primary extrinsic control
mechanism regulating HRV and cardiac
performance. It has been shown that
chronic hyperglycemia promotes pro-
gressive autonomic neural dysfunction in
a manner that parallels the development
of peripheral neuropathy, e.g., beginning
distally and progressing proximally. The
vagusnerve,thelongestautonomicnerve,
mediates 75% of all parasympathetic
activity. Because neuropathy is seen ﬁrst
in the longest ﬁbers, the earliest mani-
festations of autonomic neuropathy in
diabetes tend to be associated with para-
sympathetic denervation. As such, the
initial development of CAN in diabetes is
characterized by early augmentation of
sympathetic tone (9). Our data (10) and
those of others (11) conﬁrm that early in
theprogressionofCANcomplicatingtype
1 diabetes, there is a compensatory in-
crease in the cardiac sympathetic tone in
response to subclinical peripheral dener-
vation. Sympathetic denervation follows
later beginning at the apex of the ventri-
cles and progressing toward the base
(Fig. 1).
The initial augmentation in cardiac
sympathetic activity with subsequent ab-
normalnorepinephrinesignalingandme-
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oxidative stress (12), and calcium-
dependent apoptosis (13) may contribute
to myocardial injury (12,14) and may ex-
plain the high risk of cardiac events and
sudden death in these patients. The sym-
pathetic imbalance associated with CAN
may critically inﬂuence myocardial sub-
strate utilization (15) and contribute to
mitochondrial uncoupling (16), regional
ventricular motion abnormalities, func-
tional deﬁcits, and cardiomyopathy (10).
CLINICAL SIGNS— Clinical symp-
toms of autonomic dysfunction may not
appear until long after diabetes onset.
However, subclinical CAN, manifested as
changesinHRV,maybedetectedwithin1
year of diagnosis in type 2 diabetes and
within 2 years of diagnosis in type 1 dia-
betes (17).
Impaired HRV
The earliest clinical indicator of CAN is a
decreaseinHRV.Variabilityintheinstan-
taneousbeat-to-beatheartrateintervalsis
afunctionofsympatheticandparasympa-
thetic activity that regulates the cardiac
functional response to the body’s level of
metabolic activity. In normal individuals
the heart rate has a high degree of beat-
to-beat variability and HRV ﬂuctuates
with respiration—increasing with inspi-
ration and decreasing with expiration.
Initially, clinical relevance of HRV was
identiﬁed through observations that fetal
distress is preceded by alterations in beat-
to-beat intervals before any appreciable
change occurs in heart rate itself. The se-
rious implications of abnormal HRV be-
came apparent only in the late 1980s,
when it was conﬁrmed that HRV was a
strong, independent predictor of mortal-
ity after acute myocardial infarction (18).
Resting tachycardia
Resting heart rates of 100 bpm with oc-
casional increments up to 130 bpm usu-
allyoccurlaterinthecourseofthedisease
and reﬂect a relative increase in the sym-
pathetic tone associated with vagal im-
pairment. However, increased resting
heart rate may reﬂect other conditions
such as anemia or thyroid dysfunction
andisnotconsideredtoprovideareliable
diagnosticcriterionofCANintheabsence
of other signs. A ﬁxed heart rate that is
unresponsivetomoderateexercise,stress,
orsleepindicatesalmostcompletecardiac
denervation (19) and is indicative of se-
vere CAN.
Exercise intolerance
Autonomic dysfunction may impair exer-
cise tolerance and has been shown to re-
duce heart rate, blood pressure, and
cardiac output responses to exercise (19).
It is generally recommended that diabetic
patients suspected to have CAN be tested
with a cardiac stress test before undertak-
ing an exercise program. Patients with
CAN need to rely on their perceived ex-
ertion, not heart rate, to avoid hazardous
levels of exercise intensity (19).
Abnormal blood pressure regulation
At night, nondiabetic subjects exhibit a
predominance of vagal tone and de-
creasedsympathetictone,associatedwith
reduction in nocturnal blood pressure
(20). In diabetic CAN this pattern is al-
tered, resulting in sympathetic predomi-
nance during sleep and subsequent
nocturnal hypertension (21). These are
associated with a higher frequency of left
ventricular(LV)hypertrophyandbothfa-
tal and severe nonfatal cardiovascular
events in diabetic CAN subjects (22,23).
Orthostatic hypotension
In diabetes, orthostatic hypotension oc-
curs largely as a consequence of efferent
sympathetic vasomotor denervation,
causing reduced vasoconstriction of the
splanchnic and other peripheral vascular
beds (24). Symptoms associated with or-
thostatic hypotension include: lighthead-
ness, weakness, faintness, dizziness, visual
impairment, and, in most severe cases, syn-
cope on standing. These symptoms can be
aggravatedbyanumberofdrugsincluding:
vasodilators, diuretics, phenothiazines, in-
sulin (through endothelium-dependent
vasodilatation), and tricyclic antidepres-
sants, a class of drugs commonly used for
symptomaticreliefofpainassociatedwith
painfuldiabeticneuropathy(19).Asillus-
tratedinthecasepresentation,orthostatic
hypotension is associated with poor qual-
ity of life.
CLINICAL EVALUATION
AND DIAGNOSIS
CRITERIA— There is no widely ac-
ceptedsingleapproachtothediagnosisof
CAN in diabetes. Assessment of HRV, or-
thostatic hypotension, and 24-h blood
pressureproﬁlesprovidesindexesofboth
parasympathetic and sympathetic auto-
nomicfunctionandcanbeusedinclinical
settings. Other methods such as cardiac
sympatheticimaging,microneurography,
occlusion plethysmography, and barore-
ﬂex sensitivity are currently used pre-
dominantly in research settings but may
ﬁnd a place in the clinical assessment of
CAN in the future.
HRV
HRV provides a noninvasive and objec-
tive method for assessing cardiovagal
function and may be derived from elec-
trocardiogram recordings under paced
breathing. Incorporating respiratory sig-
Figure 1—The autonomic innervation of the heart and the effects of diabetes. It has been shown
thatindiabetes,inafashionthatparallelsthedevelopmentofperipheralneuropathy,whichbegins
atthetipofthetoesandcanprogressproximally,neuropathyaffectingtheheartbeginsattheapex
of the ventricles and progresses toward the base.
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measure both sympathetic and parasym-
pathetic branches of the autonomic ner-
vous system.
During the 1970s, Ewing et al. (25)
devised a number of simple bedside tests
of short-term R-R differences to detect
CAN in diabetic patients, including:
changes in R-R with deep breathing,
which measures sinus arrhythmia during
quiet respiration and primarily reﬂects
parasympathetic function (26); R-R re-
sponse to standing, which induces reﬂex
tachycardia followed by bradycardia and
is jointly vagal and baroreﬂex mediated;
and Valsalva ratio, which evaluates car-
diovagal function in response to a stan-
dardized increase in intrathoracic
pressure (Valsalva maneuver), primarily
parasympathetic mediated (26). These
validated tests, described in detail in a
statementbytheAmericanDiabetesAsso-
ciation (27), are recommended for CAN
diagnosis (7,26–28) and can be per-
formed in the practitioner’s ofﬁce. The
rapid postural changes that are part of
head-up-tilt-table testing, with/without
pharmacological provocation, can be
used for the investigation of CAN or of
predisposition to neurally mediated (va-
sovagal) syncope due to the wide range of
changes in the autonomic input to the
heart and in the R-R intervals. This test
requires specialized personnel and is not
readily available in general practice.
HRV with deep breathing is the most
widely used test of cardiovagal function
and has about 80% speciﬁcity (29).
TheR-Rvariationcanbeanalyzedina
numberofdifferentways,includingheart
rate range, heart period range, standard
deviation (SD), E-to-I ratio (ratio of the
shortest R-R during inspiration to the
longest R-R during expiration). Calcula-
tion of mean circular resultant computed
by vector analysis eliminates the effects of
trends in heart rate over time, attenuating
the effect of basal heart rate and ectopic
beats(30).TheValsalvaandposturaltests
are analyzed as the quotient of the largest
and shortest R-R intervals recorded dur-
ing each respective maneuver.
Normative cutpoints had been rec-
ommendedoriginallyforinterpretationof
the various HRV indexes (25). Recent
studies demonstrate that HRV is affected
mainly by age, rate of breathing, and pos-
sibly sex (26,30). Therefore, adjustments
for these variables are recommended for
higher accuracy (19,26,30).
Cardiovagalfunctioncanalsobeeval-
uated using statistical indexes in the time
and frequency domains. Time domain
measures of the normal R-R intervals in-
clude mean normal-to-normal (NN) in-
terval, mean heart rate, the difference
between the longest and shortest NN in-
terval, and the variation during the differ-
ence between night and day heart rate
(18). Twenty-four–hour R-R recordings
allow calculation of more complex statis-
ticaltimedomainmeasures,suchasSDof
all normal R-R intervals (SDNN), SD of
5-min average of normal R-R intervals
(SDANN), root–mean square of the dif-
ference of successive R-R intervals
(rMSSD),andthenumberofinstancesper
hour in which two consecutive R-R inter-
valsdifferby50msover24h(pNN50).
SDNN is thought to represent joint sym-
pathetic and parasympathetic modula-
tion of HRV, and rMSSD and pNN50 are
speciﬁc for the parasympathetic limb
(18). The accuracy of these measures can
beaffectedbyvariousarrhythmiasandre-
quire normal sinus rhythm and atrioven-
tricular-nodal function.
Spectral analysis of HRV is another
tool to evaluate CAN (19). It decomposes
the R-R signal into a set of sine and cosine
waves and estimates the magnitude of
variability as a function of frequency. The
main frequency components described
are very-low-frequency components
(0.04 Hz) related to ﬂuctuations in va-
somotor tone associated with thermoreg-
ulation, the low-frequency component
(0.04–0.15 Hz) associated with the
baroreceptorreﬂex,andthehigh-frequency
components (0.15–0.4 Hz) related to re-
spiratory activity (19). It is generally
thought that the sympathetic system
modulates the lower-frequency HRV
components, whereas the parasympa-
thetic system controls the high-frequency
HRV components. Different mathemati-
cal methods have been used to analyze
HRV. Fourier transform is the most com-
monlychosenduetoalgorithmsimplicity
and high processing speed (18). This
method, limited to stationary signals, is
based on the assumption of steady-state
conditions discarding any dynamics in
the power spectrum and does not allow a
precise detection of a sudden change in
autonomoustoneorapreciselocalization
of a particular event in time when exam-
ining nonstationary conditions (31). The
continuous wavelet transform equations
perform a time-frequency decomposition
of the signal yielding a time-dependent
version of the typical low- and high-
frequency peaks (31,32). Commercially
available software programs using these
methods are available for assessment of
HRV (ANSAR, Philadelphia, PA, and Ho-
kanson, Bellevue, WA).
Orthostatic hypotension
Orthostatic hypotension is documented
by a fall 30 mmHg in systolic or 10
mmHg in diastolic blood pressure in re-
sponse to a postural change from supine
to standing (19). There are some contro-
versial aspects related to the cut-off value
for the diagnostic fall in systolic blood
pressure, i.e., 30 mmHg (7) or 20 mmHg
(24,33), despite the deﬁnition provided
by an ad hoc consensus committee in
1996 (24). Recent evidence suggests that
postural hypotension has only moderate
concordancewithHRVinthediagnosisof
CAN (33).
Imaging techniques for CAN
Quantitative scintigraphic assessment of
sympathetic innervation of the human
heart is possible with positron emission
tomography (PET) and either [
123I]meta-
iodobenzylguanidine (MIBG) or [
11C]-
meta-hydroxy-ephedrine ([
11C]HED)
(19,34). Deﬁcits of LV [
123I]MIBG and
[
11C]HED retention have been identiﬁed
intype1andtype2diabeticsubjects(35–
37)with(35–37)andwithout(10)abnor-
mal cardiovascular reﬂex testing.
Metabolicallystable[
11C]HEDundergoes
highly speciﬁc uptake into sympathetic
nerve varicosities via norepinephrine
transporters, and quantitative [
11C]HED
retention may be assessed in 480 inde-
pendent LV regions (34). The striking
consistencyoftheevolutionofthepattern
ofdenervationintype1diabetessupports
the reliability of [
11C]HED to monitor
changes in cardiac sympathetic nerve
populations and evaluate early anatomi-
cal regional deﬁcits of sympathetic dener-
vation (10,34,35). As an example, Fig. 2
shows the polar map analysis of LV
[
11C]HED retention in subjects with type
1 diabetes expressed as Z score analysis
versus control subjects (10).
Quantitative regional measurements
of myocardial -adrenoreceptor density
can also be assessed using PET and the
high-afﬁnity -adrenoreceptor radioli-
gand [
11C]CGP-12177 (38). However,
postsynaptic -adrenoreceptor density
was never assessed in human diabetes.
Baroreﬂex sensitivity
Baroreﬂex sensitivity (BRS) is a technique
that evaluates the capability to reﬂexively
increase vagal activity and decrease sym-
pathetic activity in response to a sudden
Cardiac autonomic neuropathy in diabetes
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research protocols to assess cardiac vagal
and sympathetic baroreﬂex function and
iscalculatedfromthemeasurementofthe
heart rate–blood pressure relation after
an intravenous bolus of phenylephrine
(39). The BRS was a signiﬁcant indepen-
dent risk predictor of cardiac mortality in
the Autonomic Tone and Reﬂexes After
Myocardial Infarction (ATRAMI) study, a
large international multicenter prospec-
tive study of 1,284 patients with a recent
myocardial infarction (39). It has been
shown that the analysis of spontaneous
baroreﬂex sequences gives results equiv-
alent to the pharmacological methods,
which lead to development of techniques
based on servoplethysmomanometry that
measuresbloodpressureintheﬁngerona
beat-to-beat basis (Finapress) (19).
Microneurography
Thistechniqueisbasedonrecordingelec-
trical activity emitted by peroneal, tibial,
or radial muscle sympathetic nerves and
identiﬁcation of sympathetic bursts.
Bursts have a characteristic shape consist-
ingofagradualriseandfallthatisusually
constrained by the cardiac cycle and at
least twice the amplitude of random ﬂuc-
tuations (40). Recently available fully
automated sympathetic neurogram tech-
niques provide a rapid and objective
method that is minimally affected by sig-
nal quality and preserves beat-by-beat
sympathetic neurograms (40).
Assessment of symptoms
Symptoms associated with CAN include
exercise intolerance, orthostatic intoler-
ance, and syncope (41). The correlation
between symptom scores and deﬁcits is
generally weak in mild CAN, as these
symptoms usually occur late in the dis-
ease process. Low et al. (41), using a val-
idated self-report measure of autonomic
symptoms in a population-based study,
found that autonomic symptoms were
present more commonly in type 1 than in
type 2 diabetes. At least one autonomic
symptom was reported in 83% of a large
cohort of patients with type 2 diabetes
(42). The risk of CAN as measured by
HRV was positively associated with the
number of reported autonomic symp-
toms (42).
CLINICAL IMPLICATIONS
Mortality risk
CAN is associated with a high risk of car-
diac arrhythmias and with sudden death.
Longitudinal studies of subjects with
CAN have shown 5-year mortality rates
16–50% in type 1 and type 2 diabetes,
with a high proportion attributed to sud-
den cardiac death (25,42,43). In the
EURODIAB Prospective Cohort Study of
2,787 type 1 diabetic patients, CAN was
the strongest predictor for mortality dur-
ing a 7-year follow-up, exceeding the ef-
fect of traditional cardiovascular risk
factors (44). The Hoorn study reported
that the presence of diabetic CAN dou-
bledthe9-yearmortalityriskinanelderly
cohort (45). A meta-analysis of 15 studies
including2,900subjectswithdiabetesre-
ported a pooled relative risk of mortality
of 3.45 (95% CI 2.66–4.47) in patients
with CAN, with a progressive increase in
theriskwiththeincreaseinthenumberof
abnormal CAN function tests (46). The
higher predictive value of an increased
number of CAN abnormalities was con-
ﬁrmedmorerecentlyintwoothercohorts
oftype1andtype2diabetesshowingthat
a combined abnormality in HRV and QT
index was a strong predictor of mortality
independent of conventional risk factors
(47,48).
The increased mortality risk associ-
ated with CAN has important implica-
tions for diabetes management. A feared
consequenceofrigorousglycemiccontrol
isanincreasedincidenceofhypoglycemia
(49,50).Hypoglycemiaimpairshormonal
and autonomic responses to subsequent
hypoglycemia (51). Hypoglycemia un-
awareness may promote a reduced
threshold for malignant arrhythmias and
subsequent sudden cardiac death, which
was a possible reason for the sudden
death experienced by the patient dis-
cussed in vignette. Thus, a recent study
reported that exposure to hypoglycemia
leads to impaired CAN function in
healthy volunteers (52).
Silent myocardial ischemia and
diabetic cardiomyopathy
In a meta-analysis of 12 published stud-
ies, Vinik et al. (7) reported a consistent
association between CAN and the pres-
ence of silent myocardial ischemia, mea-
suredbyexercisestresstesting,withpoint
estimates for the prevalence rate ratios
from 0.85 to 15.53. In the Detection of
Ischemia in Asymptomatic Diabetics
(DIAD) study of 1,123 patients with type
2 diabetes, CAN was a strong predictor of
silent ischemia and subsequent cardio-
vascular events (53). The association be-
tween CAN and silent ischemia has
important implications, as reduced ap-
preciation for ischemic pain impairs
timely recognition of myocardial isch-
emia or infarction, thereby delaying
appropriate therapy. In patients with dia-
betes, presence of symptoms such acute
onsetdyspneawith/withoutcoughing,se-
vere fatigue, and/or acute onset of nausea
and vomiting should raise a high index of
suspicion for an ischemic event and
prompt the appropriate measures (19).
The presence of CAN was also
linked to the development of diabetic
cardiomyopathy in type 1 diabetes be-
cause in these patients LV dysfunction
often precedes or occurs in the absence
of signiﬁcant coronary artery disease or
hypertension. We have identiﬁed dia-
stolic dysfunction early in the course of
type 1 diabetes that correlated with ab-
normal cardiac sympathetic imaging
(10). Further studies are needed to clar-
ify the complex interactions between
CAN, silent myocardial ischemia, and
cardiomyopathy in diabetes.
Figure2—Polarmapsof[
11C]HEDretentioninnormalcontrolsubjects(left)andtype1diabetic
patients with CAN (right). The color table is set to a maximum [
11C]HED retention index value
of0.09mlblood min
1 ml
1tissue.Toquantifythe“extent”ofcardiacsympatheticdenervation,
patients’ retention index data are statistically compared with our normal population database
using Z score analysis.
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cardiovascular instability
Observations in diabetic patients under-
going general anesthesia reported that in-
dividuals with CAN required vasopressor
support more often than those without
CAN (19). Individuals with CAN may ex-
perienceagreaterdeclineinheartrateand
blood pressure during induction of anes-
thesia and more severe intraoperative hy-
pothermia resulting in decreased drug
metabolism and impaired wound healing
(19).
Stroke
Arecentstudyin1,458patientswithtype
2diabetesreportedthatpresenceofCAN,
assessed by standard HRV testing, was
one of the strongest predictors of isch-
emic stroke in this cohort together with
ageandhypertension(54).Earlierreports
showed similar associations (19).
THERAPEUTIC APPROACHES
Glycemic control
The DCCT demonstrated that intensive
insulin therapy for type 1 diabetes re-
ducedtheincidenceofCANby53%com-
pared with conventional therapy (1). The
Epidemiology of Diabetes Interventions
and Complications (EDIC) study, the
prospective observational study of the
DCCT cohort, has shown persistent ben-
eﬁcial effects of past glucose control on
microvascular complications despite the
loss of glycemic separation (55). Recently
we evaluated CAN in 1,226 well-
characterized EDIC participants during
the 13th and 14th year of EDIC follow-
up.WefoundthatduringEDICCANpro-
gressed substantially in both treatment
groups, but the prevalence and incidence
of CAN remained signiﬁcantly lower in
the former intensive group than in the
former conventional group, despite simi-
lar levels of glycemic control in the EDIC
study (56). Treatment group differences
in the mean A1C level during the DCCT
andtheEDICstudyexplainedvirtuallyall
ofthebeneﬁcialeffectsofintensiveversus
conventional therapy on risk of incident
CAN, supporting the concept that inten-
sive treatment of type 1 diabetes should
be initiated as early as is safely possible
(56).
In type 2 diabetes, the effects of gly-
cemic control are less conclusive. The VA
Cooperative Study demonstrated no dif-
ference in the prevalence of autonomic
neuropathy in type 2 diabetic patients af-
ter 2 years of tight glycemic control com-
pared with those without tight control
(57).Ontheotherhand,theSteno-2Trial
reported that a targeted, intensive inter-
vention involving glucose control and
multiple cardiovascular risk factors re-
duced the prevalence of CAN among
patients with type 2 diabetes and mi-
croalbuminuria (58).
Other therapies
Data regarding the impact of lifestyle in-
terventions in preventing progression of
CANareemerging.Strictlysuperviseden-
durance training combined with dietary
changes was associated with weight loss
and improved HRV in patients with min-
imal abnormalities (19). In the Diabetes
Prevention Program, indexes of CAN im-
proved most in the lifestyle modiﬁcation
armcomparedwiththemetforminorpla-
cebo arm.
ACE inhibitors, angiotensin receptor
blockers, or aldose reductase inhibitors
appear promising but are yet to be vali-
dated (19).
Orthostatic hypotension
The treatment of orthostatic hypotension
is challenging. Nonpharmacological
treatments include avoidance of sudden
changes in body posture to the head-up
position; avoiding medications that ag-
gravate hypotension, such as tricyclic an-
tidepressants and phenothiazines; eating
small, frequent meals to avoid postpran-
dial hypotension; and avoiding activities
that involve straining, since increased
intra-abdominal and intra-thoracic pres-
sure decrease venous return (19). Several
physicalcountermaneuvers,suchasleg
crossing, squatting, and muscle pump-
ing can help maintain blood pressure
during daily activities by inducing in-
creased cardiac ﬁlling pressures and
stroke volume.
PHARMACOLOGICAL
TREATMENTS
Midodrine
Midodrine, a peripheral-selective 1-
adrenoreceptor agonist is the only Food
and Drug Administration–approved
agent for the treatment of orthostatic hy-
potension in doses of 2.5–10 mg three
times/day.Severaldouble-blind,placebo-
controlled studies have documented its
efﬁcacyinthetreatmentoforthostatichy-
potension(7).Itdoesnotcrosstheblood-
brain barrier, resulting in fewer central
side effects. The main adverse effects are
piloerection, pruritis, paresthesias, uri-
nary retention, and supine hypertension.
Fludrocortisone acetate
Fludrocortisone acetate, a synthetic min-
eralocorticoid with a long duration of ac-
tion, induces plasma expansion and may
enhance the sensitivity of blood vessels to
circulating catecholamines (59). The ef-
fects usually occur over a 1- to 2-week
period. Supine hypertension, hypokale-
mia, and hypomagnesemia may occur.
Caution must be used, particularly in
patientswithcongestiveheartfailure,to
avoid ﬂuid overload. Treatment with
ﬂudrocortisone should begin with 0.05
mg at bedtime and may be titrated grad-
ually to a maximum of 0.2 mg/day.
Doses up to 0.3–0.4 mg used in refrac-
tory cases are associated with high risk
for hypokalemia, excessive ﬂuid reten-
tion, hypertension, and congestive heart
failure.
Erythropoietin
Erythropoietin may improve orthostatic
hypotension, but the mechanism of ac-
tion for this pressor effect is still unre-
solved. Possibilities include the increase
inredcellmassandcentralbloodvolume,
correction of the normochromic normo-
cytic anemia that frequently accompanies
severe CAN, and direct or indirect neuro-
humoral effects on the vascular wall and
vascular tone regulation mediated by the
interaction between hemoglobin and the
vasodilator nitric oxide (59). Erythropoi-
etinisadministeredsubcutaneouslyorin-
travenously at doses of 25–75 units/kg
three times a week until the hematocrit
level approaches normal followed by
lower maintenance doses (25 units/kg
three times/week) (59).
Nonselective -blockers
Nonselective -blockers, particularly
those with intrinsic sympathomimetic ac-
tivity,mayhavealimitedroleinthetreat-
mentoforthostatichypotension(59).The
suggested mechanism of action of these
agents is the blockade of vasodilat-
ing -2 receptors allowing unopposed
-adrenoreceptor–mediated vasocon-
striction. To date there is no clear efﬁcacy
evidence in diabetic CAN.
Clonidine
Clonidine, an -2 antagonist, produces a
central sympatholytic effect and a conse-
quentdecreaseinbloodpressure.Patients
with severe CAN have little central sym-
pathetic efferent activity, and the use of
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in an increase in venous return without a
signiﬁcant increase in peripheral vascular
resistance. Its use is limited by the incon-
sistent hypertensive effect and serious
side effects.
Somatostatin analogs
Somatostatin analogs (25–200 g/day)
may attenuate orthostatic hypotension in
patients with CAN by inhibiting the re-
lease of vasoactive gastrointestinal pep-
tides, enhancing cardiac output, and
increasing forearm and splanchnic vascu-
lar resistance. However, severe cases of
hypertensionwerereportedwiththeiruse
in patients with diabetic CAN (60).
Pyridostigmine bromide
Pyridostigmine bromide, a cholinesterase
inhibitor, was recently shown to amelio-
rate orthostatic hypotension by enhanc-
ing ganglionic transmission without
worsening supine hypertension (61).
CONCLUSIONS — CAN is a serious
chronic complication of diabetes and an
independent predictor of cardiovascular
disease mortality. As illustrated by the
case vignette and by the evidence pre-
sented in this review, CAN is associated
with a poor prognosis and poor quality of
life. Conclusive clinical evidence from
randomized prospective trials supports a
central role for hyperglycemia in the
pathogenesis of CAN, although other
metabolic and vascular factors contribute
to the disease state. The clinical presenta-
tion of CAN comprises a broad constel-
lation of symptoms and deﬁcits. Assess-
ment of HRV is an easily available tool to
document the presence of CAN. Cardiac
scintigraphic imaging with sympathetic
analogs offers more sensitive diagnostic
alternatives for research use. The treat-
ment of CAN is challenging. Recent clin-
ical evidence continues to prove the
beneﬁts of glycemic control, while the
beneﬁts of lifestyle interventions are
emerging.
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